Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/ddg.13084 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Fully guided system for position-predictable autotransplantation of teeth: A randomized clinical trial.
Int Endod J
January 2025
Department of Oral and Maxillofacial Surgery, Guangdong Engineering Research Center of Oral Restoration and Reconstruction Guangzhou Key Laboratory of Basic and Applied Research of Oral Regenerative Medicine, Affiliated Stomatology Hospital of Guangzhou Medical University, Guangzhou, China.
Aim: Autotransplantation of teeth (ATT) is a viable biological method for addressing dental defects. The objective was to achieve occlusal reconstruction-orientated ATT to enhance functionality and obtain optimal location and adjacency. This study proposes a new concept of a guide (a fully guided system) to achieve position-predictable ATT.
View Article and Find Full Text PDFGBR assisted Onlay bone grafting for the posterior maxillary horizontal ridge augmentation: a case report and literature review.
Front Bioeng Biotechnol
January 2025
Hospital of Stomatogy, Jilin University, Changchun, China.
The posterior mandible is the primary area for occlusal function. However, long-term tooth loss in the posterior mandible often leads to rapid absorption of both buccal and lingual trabecular bone plates and subsequent atrophy of the alveolar ridge. This ultimately results in horizontal bone deficiencies that complicate achieving an optimal three-dimensional placement for dental implants.
View Article and Find Full Text PDFISCT MSC committee statement on the US FDA approval of allogenic bone-marrow mesenchymal stromal cells.
Cytotherapy
January 2025
Osteoarthritis Research Program, Division of Orthopedic Surgery, Schroeder Arthritis Institute, University Health Network, Toronto, Ontario, Canada; Krembil Research Institute, University Health Network, Toronto, Ontario, Canada; Institute of Biomedical Engineering, University of Toronto, Toronto, Ontario, Canada; Department of Medicine, Division of Hematology, University of Toronto, Toronto, Ontario, Canada. Electronic address:
The December 2024 US Food and Drug Administration (FDA) approval of Mesoblast's Ryoncil (remestemcel-L-rknd)-allogeneic bone marrow mesenchymal stromal cell (MSC(M)) therapy-in pediatric acute steroid-refractory graft-versus-host-disease finally ended a long-lasting drought on approved MSC clinical products in the United States. While other jurisdictions-including Europe, Japan, India, and South Korea-have marketed autologous or allogeneic MSC products, the United States has lagged in its approval. The sponsor's significant efforts and investments, working closely with the FDA addressing concerns regarding clinical efficacy and consistent MSC potency through an iterative process that spanned several years, was rewarded with this landmark approval.
View Article and Find Full Text PDFThe TACOS Technique: A Stepwise Protocol for Alveolar Ridge Augmentation Using Customized Titanium Mesh.
Medicina (Kaunas)
January 2025
Department of Clinical Specialistic and Dental Sciences, Polytechnic University of Marche, Via Tronto, 10/A, 60126 Ancona, Italy.
Alveolar ridge resorption following tooth loss poses a significant challenge for successful dental implant placement. In cases of severe atrophy, bone augmentation is required to restore sufficient bone volume. This technical note outlines a detailed, stepwise surgical protocol for horizontal and vertical alveolar ridge augmentation using customized titanium mesh.
View Article and Find Full Text PDFCharacterization of a 3S PRAME VLD-Specific T Cell Receptor and Its Use in Investigational Medicinal Products for TCR-T Therapy of Patients with Myeloid Malignancies.
Cancers (Basel)
January 2025
Medigene Immunotherapies GmbH, 82152 Planegg-Martinsried, Germany.
Background/objectives: MDG1011 is an autologous TCR-T therapy developed as a treatment option for patients with myeloid malignancies, including acute myeloid leukemia (AML), myelodysplastic syndrome (MDS), and multiple myeloma (MM). It is specific for the target antigen PReferentially expressed Antigen in MElanoma (PRAME). The recombinant TCR used in MDG1011 recognizes PRAME VLD-peptide presented by HLA-A*02:01-encoded surface molecules.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!